We鈥檙e thrilled to announce that Eugene, a pioneering digital healthcare company, has successfully raised $129,000,000 in new funding, marking a significant milestone in our journey to empower individuals with informed healthcare choices. Born in Melbourne and serving Australia and New Zealand, Eugene has redefined the way people access genetic insights by offering the first medical grade at-home genetic testing and counselling service across the region. Our innovative approach combines convenience, quality, and accessibility, ensuring you receive best-in-class clinical care without the hassle of waiting rooms, referrals, or blood tests.
The infusion of capital will be primarily used to expand our cutting-edge saliva-based testing technology and scale up our operations, making it easier for individuals to access our services no matter where they are. This investment will further enhance our in-house team of expert genetic counsellors, who provide continuous support and guidance to every user. By leveraging advanced digital platforms, we are committed to bridging the gap between high-quality clinical care and everyday accessibility, empowering preconception, pregnancy, cancer, and heart health care journeys for thousands of people.
As we move forward, the new funding will play a critical role in research and development, tailoring our services to an even broader range of healthcare needs while ensuring regulatory excellence. Our goal remains to eliminate unnecessary barriers in healthcare and to provide personalized genetic insights directly to your home. We鈥檙e excited about the future and the many opportunities this capital brings to drive innovation in digital healthcare. Visit our website today to learn more about our clinical-grade genetic tests and discover how we鈥檙e making empowered healthcare choices accessible to everyone, everywhere.
